Share this video  

GU Cancers 2023 | ECHOS: real-world outcomes of docetaxel in patients with mCSPC

Orazio Caffo, MD, Santa Chiara Hospital, Pisa, Italy, talks on real-world outcomes of docetaxel in patients with metastatic castration-sensitive prostate cancer (mCSPC). The use of docetaxel according to the Phase III CHAARTED (NCT00309985) trial suggested a survival advantage in patients with de novo high-volume mCSPC. However, the use of docetaxel is still under debate in regard to the timing of either metastatic onset or disease burden. The ECHOS multicenter study collected real-world data of patients with mCSPC in Italy who were treated with docetaxel. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter